The dBMA Treg ≥ 21/μL correlation with integrated molecular-cytogenetic risk; the NPM mutation; the FLT3 ITD or D835 mutation; and de novo versus secondary AML and WBC are summarized in Table 4: the molecular-cytogenetic risk association (p = 0.020) was demonstrated. Here, FLT3 is linked to acute myeloid leukemia.